ADAPTIVE BIOTECHNOLOGIES (ADPT)

US00650F1093 - Common Stock

3.21  +0.32 (+11.07%)

After market: 3.2 -0.01 (-0.31%)

Fundamental Rating

3

Overall ADPT gets a fundamental rating of 3 out of 10. We evaluated ADPT against 58 industry peers in the Life Sciences Tools & Services industry. While ADPT seems to be doing ok healthwise, there are quite some concerns on its profitability. While showing a medium growth rate, ADPT is valued expensive at the moment.



1

1. Profitability

1.1 Basic Checks

ADPT had negative earnings in the past year.
In the past year ADPT has reported a negative cash flow from operations.
ADPT had negative earnings in each of the past 5 years.
ADPT had negative operating cash flow in 4 of the past 5 years.

1.2 Ratios

ADPT's Return On Assets of -34.07% is on the low side compared to the rest of the industry. ADPT is outperformed by 79.31% of its industry peers.
ADPT's Return On Equity of -73.04% is on the low side compared to the rest of the industry. ADPT is outperformed by 79.31% of its industry peers.
Industry RankSector Rank
ROA -34.07%
ROE -73.04%
ROIC N/A
ROA(3y)-26.63%
ROA(5y)-20.12%
ROE(3y)-50.16%
ROE(5y)-36.47%
ROIC(3y)N/A
ROIC(5y)N/A

1.3 Margins

Looking at the Gross Margin, with a value of 55.63%, ADPT is in the better half of the industry, outperforming 67.24% of the companies in the same industry.
ADPT's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for ADPT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 55.63%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-10.32%
GM growth 5Y-2.96%

6

2. Health

2.1 Basic Checks

ADPT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ADPT has been increased compared to 1 year ago.
Compared to 5 years ago, ADPT has more shares outstanding
There is no outstanding debt for ADPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

Based on the Altman-Z score of -1.79, we must say that ADPT is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -1.79, ADPT is not doing good in the industry: 79.31% of the companies in the same industry are doing better.
There is no outstanding debt for ADPT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.79
ROIC/WACCN/A
WACC11.95%

2.3 Liquidity

A Current Ratio of 4.66 indicates that ADPT has no problem at all paying its short term obligations.
The Current ratio of ADPT (4.66) is better than 68.97% of its industry peers.
ADPT has a Quick Ratio of 4.50. This indicates that ADPT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 4.50, ADPT is doing good in the industry, outperforming 74.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.66
Quick Ratio 4.5

5

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 2.13% over the past year.
ADPT shows a decrease in Revenue. In the last year, the revenue decreased by -8.11%.
ADPT shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 25.04% yearly.
EPS 1Y (TTM)2.13%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-7.14%
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y20.06%
Revenue growth 5Y25.04%
Revenue growth Q2Q-17.06%

3.2 Future

ADPT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.41% yearly.
Based on estimates for the next years, ADPT will show a quite strong growth in Revenue. The Revenue will grow by 18.40% on average per year.
EPS Next Y3.17%
EPS Next 2Y10.18%
EPS Next 3Y11.41%
EPS Next 5YN/A
Revenue Next Year1.59%
Revenue Next 2Y13.06%
Revenue Next 3Y18.4%
Revenue Next 5YN/A

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

0

4. Valuation

4.1 Price/Earnings Ratio

ADPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year ADPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y10.18%
EPS Next 3Y11.41%

0

5. Dividend

5.1 Amount

ADPT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

ADAPTIVE BIOTECHNOLOGIES

NASDAQ:ADPT (3/28/2024, 8:00:00 PM)

After market: 3.2 -0.01 (-0.31%)

3.21

+0.32 (+11.07%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap465.74M
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -34.07%
ROE -73.04%
ROCE
ROIC
ROICexc
ROICexgc
OM N/A
PM (TTM) N/A
GM 55.63%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.26
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 4.66
Quick Ratio 4.5
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)2.13%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y3.17%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-8.11%
Revenue growth 3Y20.06%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y